umeclidinium bromide (UMEC) — Competitive Intelligence Brief

umeclidinium bromide (UMEC) (umeclidinium bromide (UMEC)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA). Area: Respiratory / Pulmonology.

marketed Long-acting muscarinic antagonist (LAMA) Muscarinic M3 receptor Respiratory / Pulmonology Small molecule

Target snapshot

umeclidinium bromide (UMEC) (umeclidinium bromide (UMEC)) — GlaxoSmithKline. Umeclidinium bromide is a long-acting muscarinic antagonist (anticholinergic) that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
umeclidinium bromide (UMEC) TARGET	umeclidinium bromide (UMEC)	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor
Salbutamol + Tiotropium	Salbutamol + Tiotropium	IRCCS Azienda Ospedaliero-Universitaria di Bologna	marketed	Combination bronchodilator (short-acting beta-2 agonist + long-acting anticholinergic)	Beta-2 adrenergic receptor (salbutamol); Muscarinic M3 receptor (tiotropium)
Tiotropium + formoterol/beclometasone	Tiotropium + formoterol/beclometasone	KU Leuven	marketed	Long-acting anticholinergic/long-acting beta-2 agonist/inhaled corticosteroid combination	Muscarinic M3 receptor, beta-2 adrenergic receptor, glucocorticoid receptor
tolterodine , mirabegron	tolterodine , mirabegron	Far Eastern Memorial Hospital	marketed	Antimuscarinic and beta-3 adrenergic agonist combination	Muscarinic M3 receptor and beta-3 adrenergic receptor
TIO	TIO	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor
Tiotropium & olodaterol	Tiotropium & olodaterol	University of Dundee	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
UMEC/VI DPI	UMEC/VI DPI	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) class)

1. GlaxoSmithKline · 9 drugs in this class
2. AstraZeneca · 3 drugs in this class
3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
4. Chiesi Farmaceutici S.p.A. · 1 drug in this class
5. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
6. Lupin, Inc. · 1 drug in this class
7. Sanofi · 1 drug in this class